ePrints

Therapy of childhood acute myelogenous leukemias

Lookup NU author(s): Professor Hermann Josef Vormoor

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in children. Although AML is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progress in improving outcome for AML patients has been achieved over the past 15 years. This can be attributed to intensification of chemotherapy, increased use of bone marrow transplantation, and improved supportive care. Thus 30-50% of children with AML achieve long-term event-free survival with current treatment strategies [61, 66, 85, 96]. This review gives an overview about the evolution of and rationale for current pediatric treatment protocols, with special emphasis on the German Berlin-Frankfurt-Munster (BFM) studies, and discusses new directions for the future.

Publication metadata

Author(s): Vormoor J, Boos J, Stahnke K, Jürgens H, Ritter J, Creutzig U

Publication type: Article

Publication status: Published

Journal: Annals of Hematology

Year: 1996

Volume: 73

Issue: 1

Pages: 11-24

Print publication date: 01/07/1996

ISSN (print): 0939-5555

ISSN (electronic): 1432-0584

URL: http://dx.doi.org/10.1007/s002770050193

DOI: 10.1007/s002770050193

Notes: 0939-5555 (Print) Journal Article Review

Altmetrics

Share